Recruitment

Recruitment Status
Unknown status

Inclusion Criteria

EGFR mutation status known with no activating EGFR mutation
patients who have signed an informed consent to participate in this study
indication of erlotinib therapy after at least one previous therapy
...
EGFR mutation status known with no activating EGFR mutation
patients who have signed an informed consent to participate in this study
indication of erlotinib therapy after at least one previous therapy
WHO activity score between 0 and 2.
life expectancy exceeding 12 weeks
NSCLC proved by a histological biopsy
age over superior to 18

Exclusion Criteria

contraindication for the initiation of erlotinib
refusal to sign the consent
infection with the HIV virus
...
contraindication for the initiation of erlotinib
refusal to sign the consent
infection with the HIV virus
major adults protected by French law
progressive inflammatory disease
life expectancy less than 12 weeks
other malignant disease

Summary

Conditions
  • No EGFR Activating Mutation
  • Non-small Cell Lung Cancer Metastatic or Non-small Cell Lung Cancer Recurrent
Type
Interventional
Phase
Phase 2
Design
  • Allocation: N/A
  • Intervention Model: Single Group Assignment
  • Masking: None (Open Label)

Participation Requirements

Age
Between 18 years and 125 years
Gender
Both males and females

Inclusion Criteria

EGFR mutation status known with no activating EGFR mutation
patients who have signed an informed consent to participate in this study
indication of erlotinib therapy after at least one previous therapy
...
EGFR mutation status known with no activating EGFR mutation
patients who have signed an informed consent to participate in this study
indication of erlotinib therapy after at least one previous therapy
WHO activity score between 0 and 2.
life expectancy exceeding 12 weeks
NSCLC proved by a histological biopsy
age over superior to 18

Exclusion Criteria

contraindication for the initiation of erlotinib
refusal to sign the consent
infection with the HIV virus
...
contraindication for the initiation of erlotinib
refusal to sign the consent
infection with the HIV virus
major adults protected by French law
progressive inflammatory disease
life expectancy less than 12 weeks
other malignant disease

Tracking Information

NCT #
NCT02069418
Collaborators
  • University Hospital, Tours
  • Army Hospital, Percy
  • Créteil Hospital
  • University Hospital, Rouen
  • Central Hospital, Nancy, France
  • University Hospital, Toulouse
  • University Hospital, Bordeaux
Investigators
  • Principal Investigator: José HUREAUX, MD, PhD University Hospital, Angers Study Chair: Olivier COUTURIER, MD, PhD University Hospital, Angers
  • José HUREAUX, MD, PhD University Hospital, Angers Study Chair: Olivier COUTURIER, MD, PhD University Hospital, Angers